The effects of vitamin D supplementation on endothelial activation among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Tabrizi, Reza; Akbari, Maryam; Lankarani, Kamran Bagheri; Heydari, Seyed Taghi; Kolahdooz, Fariba; Asemi, Zatollah

doi:10.1186/s12986-018-0320-9

Cited by 9 publications

(9 citation statements)

References 41 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Participants in our study had mean NT-proBNP concentrations that were in the normal range at baseline and rose to the upper-normal range over time, perhaps due to vitamin D 3 supplementation. This contradicts animal studies demonstrating reduced B-type natriuretic peptide (BNP) transcription with vitamin D receptor activation [29][30][31] and clinical studies reporting either a neutral or beneficial impact of vitamin D receptor agonists on markers of endothelial and cardiac function [10,27,32]. In a large cohort study of patients with systolic heart failure, low 25(OH)D levels were associated with elevated NT-proBNP [33].…”

Section: Discussionmentioning

confidence: 96%

Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis Interventions that reduce inflammation may delay progression of microvascular and macrovascular complications in diabetes. We examined the effects of vitamin D 3 and/or n-3 fatty acid supplementation vs placebo on 5 year changes in serum inflammatory and cardiac biomarkers in adults with type 2 diabetes. Methods This study reports pre-specified secondary outcomes of the Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease, in which 1312 US adults with type 2 diabetes and without known cardiovascular disease, malignancy, or endstage kidney disease were randomised using computer-generated random numbers in blocks of eight to vitamin D 3 (2000 IU/day) vs placebo and n-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]; 1 g/day) vs placebo in a 2 × 2 factorial design. Participants, examiners, and researchers assessing outcomes were blinded to intervention assignment. We measured serum IL-6, high-sensitivity C-reactive protein (hsCRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline and after 2 and 5 years. Results A total of 333 participants were randomised to vitamin D 3 and placebo n-3 fatty acids, 289 to n-3 fatty acids and placebo vitamin D 3 , 370 to vitamin D 3 and n-3 fatty acids, and 320 to 2 placebos; 989 (75%) and 934 (71%) participants returned blood samples at 2 and 5 years, respectively. Participants had a mean age of 67.6 years (46% women). Overall, baseline geometric means of IL-6, hsCRP and NT-proBNP were 1.2 pg/ml, 1.9 mg/l and 262 ng/l, respectively. After 5 years, mean IL-6 and hsCRP remained within 6% of their baseline values while mean NT-proBNP increased by 55% overall. Compared with placebo, participants assigned to vitamin D 3 had a 1.24-fold greater increase in NT-proBNP over 5 years (95% CI 1.09, 1.41; p = 0.003), while IL-6 and hsCRP did not have a significant difference in change. Comparing n-3 fatty acids with placebo, there was no significant difference in change in IL-6, hsCRP or NT-proBNP. No heterogeneity was observed in subgroup analyses accounting for baseline eGFR, urine albumin to creatinine ratio, initial biomarker concentration, 25-hydroxyvitamin D level or EPA+DHA index.

show abstract

Section: Discussionmentioning

confidence: 96%

Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Зазвичай розвиток ендотеліальної дисфункції (ЕД) асоціюють з притаманними СПКЯ метаболічними і гормональними розладами, кожен з яких може справляти негативний вплив на функцію ендотелію [2]. Однак на сьогодні у літературних джерелах також з'являються повідомлення щодо ролі недостатності вітаміну D у формуванні ЕД за умов СПКЯ [3][4][5].…”

Section: вступunclassified

Vitamin D role in endothelial dysfunction development in patients with polycystic ovarian syndrome

Arkhypkina

Bondarenko

Lyubimovа

et al. 2022

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Background. The study was aimed to determine the correlation between the blood concentration of vitamin D and factors that influence the function of the endothelium and the hemodynamic of gonads in women with polycystic ovary syndrome (PCOS). Material and methods. Sixty women aged from 18 to 26 years were examined: 30 women with a diagnosis of PCOS and 30 healthy women. The blood serum concentration of vitamin D, C-reactive protein (CRP), interleukin-6 (IL-6), homocysteine (Hcy), nitrites/nitrates (NOx), and arginine were investigated. Maximum systolic velocity (Vmax), resistance index (RI), and pulsatility index (PI) were measured with Doppler ultrasound. Cholecalciferol was used in a dose of 4000 IU per day for 12 weeks for the correction of deficiency of vitamin D. Results. The patients with PCOS were found to have a lower (Р < 0.001) average vitamin D than healthy women. The reduction of vitamin D concentration was combined with an increase (P < 0.001) in the average concentration of NOx and a decrease in arginine. It was found a positive association between vitamin D and arginine (r = 0.391; P < 0.05), between NOx and CRP (r = 0.432; P < 0.02), IL-6 (r = 0.476; P < 0.01), Vmax (r = 0.383; P < 0.05), RI (r = 0.369; P < 0.05), PI (r = 0.380; P < 0.05) and reverse correlation with arginine (r = –0.375; P < 0.05). It was not found an association between NOx and vitamin D (r = 0.207; P > 0.05), Hcy (r = 0.176; P > 0.05); between vitamin D and Vmax (r = 0.231; P > 0.05), RI (r = 0.201; P > 0.05), PI (r = 0.181; P > 0.05). The therapy of cholecalciferol level was accompanied by an increase (P < 0.001) in concentrations of vitamin D, arginine (P < 0.05) and a decrease in NOx (P < 0.02), IL-6 (P < 0.05), SRP (P < 0.001), Hcy (P < 0.001), Vmax (P < 0.001), RI (P < 0.001), PI (P < 0.01), quantity of antral follicles (P < 0.001), and the growth of follicles (P < 0.001). However, none of the studied indicators reached the indicators in healthy women. Conclusions. The deficiency of vitamin D is associated with increased markers of chronic inflammation, homocysteine, nitrate/nitrites, reduced concentration of arginine that provokes the development of endothelium dysfunction and, therefore, the hemodynamics disorders and folliculogenesis in the ovary.

show abstract

“…In metabolic syndrome, one RCT has been published in which cholecalciferol supplementation in children was associated with statistically significant decreases in insulin and serum triglycerides, as well as HOMA-IR (insulin resistance HOMA) and continuous metabolic syndrome value [ 47 ]; and another RCT showed a decrease in serum triglycerides in adults [ 48 ]. A meta-analysis of 14 RCTs (12 of which were supplemented with cholecalciferol and only 2 with ergocalciferol) has recently been published concluding that vitamin D supplementation may reduce von Willebrand factor in patients with metabolic syndrome and its related disorders [ 49 ].…”

Section: Clinical Efficacy Of Cholecalciferol and Calcifediol: Whamentioning

confidence: 99%

Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency

Henríquez

Romero

2020

Nutrients

View full text Add to dashboard Cite

Vitamin D deficiency is a global health problem due to its high prevalence and its negative consequences on musculoskeletal and extra-skeletal health. In our comparative review of the two exogenous vitamin D supplementation options most used in our care setting, we found that cholecalciferol has more scientific evidence with positive results than calcifediol in musculoskeletal diseases and that it is the form of vitamin D of choice in the most accepted and internationally recognized clinical guidelines on the management of osteoporosis. Cholecalciferol, unlike calcifediol, guarantees an exact dosage in IU (International Units) of vitamin D and has pharmacokinetic properties that allow either daily or even weekly, fortnightly, or monthly administration in its equivalent doses, which can facilitate adherence to treatment. Regardless of the pattern of administration, cholecalciferol may be more likely to achieve serum levels of 25(OH)D (25-hydroxy-vitamin D) of 30–50 ng/mL, an interval considered optimal for maximum benefit at the lowest risk. In summary, the form of vitamin D of choice for exogenous supplementation should be cholecalciferol, with calcifediol reserved for patients with liver failure or severe intestinal malabsorption syndromes.

show abstract

The effects of vitamin D supplementation on endothelial activation among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Cited by 9 publications

References 41 publications

Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial

Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial

Vitamin D role in endothelial dysfunction development in patients with polycystic ovarian syndrome

Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency

Contact Info

Product

Resources

About